A record of what ICICI Securities Analysis said publicly, with the source. Not advice.
“Bullish on Zydus Lifesciences with a buying range of ₹1,200-1,265 and a target price of ₹1,480, indicating a potential upside of 19%. The call is made during a period of heightened market volatility, but the domestic earnings cycle remains fundamentally strong.”
ICICI Securities Analysis’s track record (trackable calls only): 265 graded calls · 95% CI 41–52%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
Entry zone: ₹1,200–₹1,265. The call starts at the first close that comes into it.
Target ₹1,480, as stated.
Window: 12 months, the default when no time frame is stated.
Window still open: no verdict until a close reaches a level or the window ends.
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.